Kaitlyn Bader

Learn more about the latest research in atopic dermatitis from Raj Chovatiya, MD, PhD, MSCI; Robert Sidbury, MD; David Rosmarin, MD; Amy Paller, MD; Melinda Gooderham, MD, MSc, FRCPC; and Jonathan Silverberg, MD, PhD, MPH.

In a milestone year for Dermatology Times, our Editorial Advisory Board reflects on advancements in their careers.

This week’s collection of the latest dermatologic studies includes drug-induced epidermal necrolysis in pediatric patients, predicting relapse in chronic spontaneous urticaria, fatigue in patients with psoriasis and psoriatic arthritis, and the role of eosinophils in hidradenitis suppurativa.

Michelle Bolas and Rukiyah T. Van Dross-Anderson, PhD, discuss the significance of NCInnovations’ funding and the clinical impact of Van Dross-Anderson's research in patients with advanced melanoma.

In a milestone year for Dermatology Times, our Editorial Advisory Board reflects on how patient interactions have changed over time.

Renata Block, MMS, PA-C, interviews dermatology clinicians and the Melanoma Research Foundation CEO at the Chicago SPF Fest.

In a milestone year for Dermatology Times, our Editorial Advisory Board reflects on key career mentors.

A systematic review of 31 studies found that patients with EBA responded well to rituximab with few adverse effects.

Iltefat Hamzavi, MD, discusses the REGINA 007 phase 2 trial evaluating MK-6194 for the treatment of non-segmental vitiligo.

In case you missed it, this week we had news about the FDA approval of deuruxolitinib for severe alopecia in adults, new nonmelanoma guidelines from the Dermatology Association of Radiation Therapy, Arcutis' submitted sNDA for roflumilast foam for scalp and body psoriasis, and more.